Evotec SE today announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bristol-myers-squibb-enter-licence-agreement-within-neuroscience-partnership-6312